Dare Bioscience (DARE) announced it has entered into an agreement with the Gates Foundation under which it will receive up to approximately $499,000 from the Gates Foundation to provide mentorship and project management support for third-party research projects addressing preeclampsia, one of the most serious and underserved complications of pregnancy. Through this engagement, Dare will provide strategic mentorship, technical guidance, and tailored project management support to Grand Challenges grantee organizations in various geographies worldwide whose pre-clinical research projects are focused on the prevention, diagnosis, and treatment of preeclampsia.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DARE:
- Daré, AMD, Twilio, UiPath, Luckin: Trending by Analysts
- Dare Bioscience upgraded to Buy from Hold at Maxim
- Daré Bioscience Engages Market with New Presentation
- Daré Bioscience’s Earnings Call: Optimism Amid Challenges
- Daré Bioscience: Strategic Growth and Market Expansion with Upcoming Sildenafil Cream Launch